How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?

Well, this is a very challenging question that certainly has come up in discussions at times over the years and I could conclude with a very simple answer: No or could offer a more twisted answer arriving at the same response- just for the fun of it, let’s do the latter.

So how would we, as a multidi...

I agree this is definitely a challenge in the field. Obviously, the main issue is the 25-35% of patients who recur in this setting. This highlights the need for the development of validated biomarkers in this space.

I will highlight one recent small study by Lebow et al., PMID 37795442 in which they ...

Most of these patients are cured with SBRT. Therefore, off-label adjuvant therapy has medical, ethical, and medical-legal risks. Choose wisely.